Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A sample-size-optimal Bayesian procedure for sequential pharmaceutical trials

N Cressie1, J Biele

  • 1Department of Statistics, Iowa State University, Ames 50011.

Biometrics
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mars sample return campaign: biological risk and a proposed sample safety assessment protocol.

Applied and environmental microbiology·2026
Same author

Low thermal inertia of carbonaceous asteroid Bennu driven by cracks observed in returned samples.

Nature communications·2026
Same author

Spatial analysis and visualization of global data on multi-resolution hexagonal grids.

Japanese journal of statistics and data science·2022
Same author

Images from the surface of asteroid Ryugu show rocks similar to carbonaceous chondrite meteorites.

Science (New York, N.Y.)·2019
Same author

Philae's first look. Philae's First Days on the Comet. Introduction.

Science (New York, N.Y.)·2015
Same author

Polarization Lidar: Correction of instrumental effects.

Optics express·2009
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
See all related articles

Optimizing pharmaceutical trials with a flexible sample-size rule can significantly increase expected net gains. This approach enhances the efficiency of sequential testing procedures beyond fixed sample sizes.

Area of Science:

  • Pharmaceutical research
  • Biostatistics
  • Clinical trial design

Background:

  • Sequential testing procedures in pharmaceutical trials often assume a constant sample size at each decision point.
  • Prior distributions for drug efficacy are derived from biological processes, animal studies, and clinical experience.
  • Previous work established optimal Bayes sequential testing with fixed sample sizes.

Purpose of the Study:

  • To introduce and evaluate an optimized sample-size rule for sequential pharmaceutical trials.
  • To demonstrate the potential for increased expected net gains by optimizing the sample-size component.
  • To improve upon existing sequential testing procedures by incorporating adaptive sample sizing.

Main Methods:

  • Bayesian statistical framework for decision-making in pharmaceutical trials.

Related Experiment Videos

  • Optimization of a sequential testing procedure with respect to a dynamic sample-size rule.
  • Financial scale used to quantify the consequences of different decisions.

    • Main Results:

    • The proposed method allows for optimization of the sample-size rule, a component often fixed in traditional procedures.
    • Optimizing the sample-size rule can lead to considerably larger expected net gains.
    • This adaptive approach can result in significantly smaller Bayes risks compared to fixed sample-size methods.

    Conclusions:

    • Incorporating an optimized sample-size rule enhances sequential pharmaceutical trial design.
    • Adaptive sample sizing offers a pathway to greater financial efficiency and reduced risk in drug development.
    • This methodology provides a more advanced approach to optimizing clinical trial efficiency and outcomes.